Skip to main content

Reline using the GORE® VIABAHN® Endoprosthesis as first line therapy when treating complex in-stent restenosis (ISR)

Case takeaways

For any complex SFA ISR, relining with covered stent grafts has become a “go to” procedure as first line therapy. The Gore RELINE Clinical Study with the GORE® VIABAHN® Endoprosthesis showed high primary patency even in the most challenging disease: 75% 12-month primary patency with an average lesion length of over 17 cm.1 In this ISR disease case, relining the BMS with a GORE® VIABAHN® Endoprosthesis produced a favorable outcome and successfully excluded the neointimal hyperplasia associated with ISR of the BMS.

TERUMO, DESTINATION and GLIDEWIRE are trademarks of Terumo Medical Corporation.
SPECTRANETICS and QUICK-CROSS are trademarks of Spectranetics Corp.
MEDTRONIC and SPIDERFX are trademarks of Medtronic, Inc.

The outcomes and observations reported are based on individual case experience and the patients treated. The steps described here may not be complete, and are not intended to be a replacement for the Instructions for Use or the education, training and professional judgment of Healthcare Providers. Healthcare Providers remain solely responsible for making decisions about patient care and the use of medical technologies.

Visit our clinical uses page

1. Bosiers M, Deloose K, Callaert J, et al. Superiority of stent-grafts for in-stent restenosis in the superficial femoral artery: twelve-month results from a multicenter randomized trial. Journal of Endovascular Therapy 2015;22(1):1-10.